COL18A1 and diabetic retinopathy: The current gene therapy research for diabetic retinopathy is to use related gene drugs against pigment epithelium-derived factor, angiostatin, endostatin, and vascular endothelial growth factor, inhibit endothelial cell proliferation, and form new blood vessels, with these to achieve the clinical purpose of prevention and treatment of diabetic retinopathy.